DarioHealth Corp
NASDAQ:DRIO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.17
30.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
DarioHealth Corp
DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. The company is headquartered in New York City, New York and currently employs 200 full-time employees. The company went IPO on 2013-03-08. DarioHealth operates at the intersection of life sciences, behavioral science, and software technology to deliver integrated and engaging digital therapeutics interventions. DarioHealth offers digital therapeutics solutions covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Its products include Dario Blood Glucose Monitoring Starter Kit and Dario Blood Pressure Monitoring System. Its Dario Blood Glucose Monitoring Starter Kit is pocket-sized smartphone blood glucose meter that measure sugar levels. Its Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all your readings in the Dario App. Its Dario mobile application, the Dario Blood sugar (glucose) meter enables to track and check blood sugar (glucose) in real-time.
DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. The company is headquartered in New York City, New York and currently employs 200 full-time employees. The company went IPO on 2013-03-08. DarioHealth operates at the intersection of life sciences, behavioral science, and software technology to deliver integrated and engaging digital therapeutics interventions. DarioHealth offers digital therapeutics solutions covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Its products include Dario Blood Glucose Monitoring Starter Kit and Dario Blood Pressure Monitoring System. Its Dario Blood Glucose Monitoring Starter Kit is pocket-sized smartphone blood glucose meter that measure sugar levels. Its Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all your readings in the Dario App. Its Dario mobile application, the Dario Blood sugar (glucose) meter enables to track and check blood sugar (glucose) in real-time.
Revenue Decline: Q3 2025 revenue came in at $5 million, down sequentially and year-over-year, mainly due to a large non-renewal and a shift toward recurring revenue.
Margin Expansion: Gross margin grew to 60% in Q3 2025, up from 55% last quarter and 52% a year ago, reflecting improvements from a software-led model.
Cost Cuts: Operating expenses fell by $3.4 million (21%) year-over-year in Q3 and by $17.2 million (31%) in the first nine months of 2025.
Client Growth: 45 new client accounts have been signed year-to-date, surpassing the 2025 target of 40 clients; client base now exceeds 125.
Recurring Revenue Focus: The company is deliberately shifting to high-margin, recurring revenue streams, with a $12.4 million new business pipeline for 2026.
Channel Partner Momentum: Over 80% of new wins came through channel partners, expanding reach to over 116 million covered lives.
Cash Position: Dario ended Q3 with $31.9 million in cash, bolstered by a $17.5 million private placement.
Breakeven Outlook: Company reiterated expectation to reach cash flow breakeven by late 2026 to early 2027.
